Literature DB >> 22934706

Cell survival signaling in neuroblastoma.

Michael L Megison1, Lauren A Gillory, Elizabeth A Beierle.   

Abstract

Neuroblastoma is the most common extracranial solid tumor of childhood and is responsible for over 15% of pediatric cancer deaths. Neuroblastoma tumorigenesis and malignant transformation is driven by overexpression and dominance of cell survival pathways and a lack of normal cellular senescence or apoptosis. Therefore, manipulation of cell survival pathways may decrease the malignant potential of these tumors and provide avenues for the development of novel therapeutics. This review focuses on several facets of cell survival pathways including protein kinases (PI3K, AKT, ALK, and FAK), transcription factors (NF-κB, MYCN and p53), and growth factors (IGF, EGF, PDGF, and VEGF). Modulation of each of these factors decreases the growth or otherwise hinders the malignant potential of neuroblastoma, and many therapeutics targeting these pathways are already in the clinical trial phase of development. Continued research and discovery of effective modulators of these pathways will revolutionize the treatment of neuroblastoma.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22934706      PMCID: PMC3710698          DOI: 10.2174/1871520611313040005

Source DB:  PubMed          Journal:  Anticancer Agents Med Chem        ISSN: 1871-5206            Impact factor:   2.505


  153 in total

Review 1.  NF-kappa B: a pleiotropic mediator of inducible and tissue-specific gene control.

Authors:  M J Lenardo; D Baltimore
Journal:  Cell       Date:  1989-07-28       Impact factor: 41.582

2.  Neuroblastoma incidence and survival in European children (1978-1997): report from the Automated Childhood Cancer Information System project.

Authors:  Claudia Spix; Guido Pastore; Risto Sankila; Charles A Stiller; Eva Steliarova-Foucher
Journal:  Eur J Cancer       Date:  2006-09       Impact factor: 9.162

3.  The neuroprotective effects of Lonicera japonica THUNB. against hydrogen peroxide-induced apoptosis via phosphorylation of MAPKs and PI3K/Akt in SH-SY5Y cells.

Authors:  Seung-Hwan Kwon; Sa-Ik Hong; Ji-Ah Kim; Yang-Hee Jung; Sun-Yeou Kim; Hyoung-Chun Kim; Seok-Yong Lee; Choon-Gon Jang
Journal:  Food Chem Toxicol       Date:  2011-01-12       Impact factor: 6.023

4.  Expression of the ALK tyrosine kinase gene in neuroblastoma.

Authors:  L Lamant; K Pulford; D Bischof; S W Morris; D Y Mason; G Delsol; B Mariamé
Journal:  Am J Pathol       Date:  2000-05       Impact factor: 4.307

5.  VEGF upregulates Bcl-2 expression and is associated with decreased apoptosis in neuroblastoma cells.

Authors:  Elizabeth A Beierle; Louise F Strande; Mike K Chen
Journal:  J Pediatr Surg       Date:  2002-03       Impact factor: 2.545

6.  The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma.

Authors:  Andrew Slack; Zaowen Chen; Roberto Tonelli; Martin Pule; Lisa Hunt; Andrea Pession; Jason M Shohet
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-11       Impact factor: 11.205

7.  Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage.

Authors:  G M Brodeur; R C Seeger; M Schwab; H E Varmus; J M Bishop
Journal:  Science       Date:  1984-06-08       Impact factor: 47.728

8.  N-myc is a novel regulator of PI3K-mediated VEGF expression in neuroblastoma.

Authors:  J Kang; P G Rychahou; T A Ishola; J M Mourot; B M Evers; D H Chung
Journal:  Oncogene       Date:  2008-02-18       Impact factor: 9.867

9.  Activation of nuclear factor kappa B in human neuroblastoma cell lines.

Authors:  M Körner; N Tarantino; O Pleskoff; L M Lee; P Debré
Journal:  J Neurochem       Date:  1994-05       Impact factor: 5.372

10.  Insulin receptor substrate (IRS)-2, not IRS-1, protects human neuroblastoma cells against apoptosis.

Authors:  Bhumsoo Kim; Eva L Feldman
Journal:  Apoptosis       Date:  2009-05       Impact factor: 4.677

View more
  14 in total

1.  Safety of bevacizumab in patients younger than 4 years of age.

Authors:  N C Millan; M J Poveda; O Cruz; J Mora
Journal:  Clin Transl Oncol       Date:  2015-08-29       Impact factor: 3.405

2.  Tideglusib attenuates growth of neuroblastoma cancer stem/progenitor cells in vitro and in vivo by specifically targeting GSK-3β.

Authors:  Hisham F Bahmad; Reda M Chalhoub; Hayat Harati; Georges Daoud; Youssef Fares; Wassim Abou-Kheir; Jolie Bou-Gharios; Sahar Assi; Farah Ballout; Alissar Monzer; Hiba Msheik; Tarek Araji; Mohamad K Elajami; Paola Ghanem; Farah Chamaa; Humam Kadara; Tamara Abou-Antoun
Journal:  Pharmacol Rep       Date:  2020-10-08       Impact factor: 3.024

Review 3.  The significance of PAK4 in signaling and clinicopathology: A review.

Authors:  Xinbo Yu; Changwei Huang; Jiyuan Liu; Xinyu Shi; Xiaodong Li
Journal:  Open Life Sci       Date:  2022-06-20       Impact factor: 1.311

4.  Synthetic high-density lipoprotein nanoconjugate targets neuroblastoma stem cells, blocking migration and self-renewal.

Authors:  Chitra Subramanian; Peter T White; Rui Kuai; Avinaash Kalidindi; Valerie P Castle; James J Moon; Barbara N Timmermann; Anna Schwendeman; Mark S Cohen
Journal:  Surgery       Date:  2018-05-09       Impact factor: 3.982

5.  Low UBE4B expression increases sensitivity of chemoresistant neuroblastoma cells to EGFR and STAT5 inhibition.

Authors:  Kimiya Memarzadeh; David J Savage; Andrew J Bean
Journal:  Cancer Biol Ther       Date:  2019-09-01       Impact factor: 4.742

6.  Different inhibition of Gβγ-stimulated class IB phosphoinositide 3-kinase (PI3K) variants by a monoclonal antibody. Specific function of p101 as a Gβγ-dependent regulator of PI3Kγ enzymatic activity.

Authors:  Aliaksei Shymanets; Oscar Vadas; Cornelia Czupalla; Jaclyn LoPiccolo; Michael Brenowitz; Alessandra Ghigo; Emilio Hirsch; Eberhard Krause; Reinhard Wetzker; Roger L Williams; Christian Harteneck; Bernd Nürnberg
Journal:  Biochem J       Date:  2015-07-01       Impact factor: 3.857

Review 7.  The role of intracellular calcium for the development and treatment of neuroblastoma.

Authors:  Noothan Jyothi Satheesh; Dietrich Büsselberg
Journal:  Cancers (Basel)       Date:  2015-05-22       Impact factor: 6.639

Review 8.  A critical evaluation of PI3K inhibition in Glioblastoma and Neuroblastoma therapy.

Authors:  Mike-Andrew Westhoff; Georg Karpel-Massler; Oliver Brühl; Stefanie Enzenmüller; Katia La Ferla-Brühl; Markus D Siegelin; Lisa Nonnenmacher; Klaus-Michael Debatin
Journal:  Mol Cell Ther       Date:  2014-10-27

9.  The novel thiosemicarbazone, di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone (DpC), inhibits neuroblastoma growth in vitro and in vivo via multiple mechanisms.

Authors:  Zhu-Ling Guo; Des R Richardson; Danuta S Kalinowski; Zaklina Kovacevic; Kian Cheng Tan-Un; Godfrey Chi-Fung Chan
Journal:  J Hematol Oncol       Date:  2016-09-27       Impact factor: 17.388

10.  Surface marker profiling of SH-SY5Y cells enables small molecule screens identifying BMP4 as a modulator of neuroblastoma differentiation.

Authors:  Fraua Christina Ferlemann; Vishal Menon; Alexandra Larisa Condurat; Jochen Rößler; Jan Pruszak
Journal:  Sci Rep       Date:  2017-10-19       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.